hepat
b
viru
hbv
small
dna
viru
chronic
infect
million
peopl
worldwid
caus
approxim
death
annual
due
variou
sever
liver
diseas
includ
cirrhosi
hepatocellular
carcinoma
hcc
liver
failur
current
approv
directact
antivir
agent
hbv
six
nucleo
ide
analogu
inhibit
viral
dna
polymeras
vari
potenc
barrier
drug
resist
although
viral
dna
polymeras
inhibitor
significantli
reduc
viral
load
prevent
liver
diseas
progress
rare
cure
hbv
infect
due
inabl
erad
cccdna
hbv
core
protein
small
polypeptid
amino
acid
residu
exist
infect
hepatocyt
sever
distinct
quaternari
structur
play
multipl
role
viral
replic
cycl
best
character
function
core
protein
assembl
pregenom
pg
rna
viral
dna
polymeras
complex
nucleocapsid
hbv
dna
synthesi
take
place
moreov
tempor
spatial
regul
disassembl
uncoat
nucleocapsid
essenti
deliveri
viral
relax
circular
rc
genom
dna
nuclei
infect
hepatocyt
convert
coval
close
circular
ccc
dna
furthermor
also
suggest
core
protein
may
associ
cccdna
minichromosom
asyet
undefin
structur
manner
regul
transcript
interestingli
also
report
core
protein
hijack
host
immun
respons
recruit
cytokineinduc
dna
cytosin
deaminas
cccdna
minichromosom
result
cytosin
deamin
decay
cccdna
due
uniqu
structur
essenti
role
viral
replic
disrupt
interfer
nucleocapsid
assembl
andor
disassembl
small
molecular
core
protein
alloster
modul
cpam
repres
new
frontier
develop
novel
antivir
agent
hbv
last
two
decad
least
five
chemotyp
cpam
report
compound
bind
hydrophob
pocket
design
hap
pocket
dimerdim
interfac
near
ctermini
core
protein
subunit
bind
molecul
hap
pocket
induc
larg
scale
alloster
conform
chang
core
protein
subunit
alter
capsid
assembl
kinet
pathway
heteroaryldihydropyrimidin
hap
bay
misdirect
capsid
assembl
form
noncapsid
polym
core
protein
chemotyp
cpam
includ
sulfamoylbenzamid
sba
phenylpropenamid
ppa
repres
respect
fig
induc
format
morpholog
normal
empti
capsid
distinct
quaternari
andor
tertiari
structur
chang
thu
preclud
viral
dna
replic
thu
far
sever
hap
sba
shown
inhibit
hbv
replic
anim
model
current
preclin
clinic
develop
inspir
observ
small
molecul
compound
target
capsid
protein
dengu
viru
dual
effect
assembl
disassembl
uncoat
viral
capsid
hypothes
hbv
cpam
may
disrupt
capsid
assembl
also
alter
structur
function
assembl
nucleocapsid
consequenti
affect
viral
dna
replic
andor
cccdna
synthesi
inde
obtain
evid
show
hap
sba
ppa
induc
disassembl
nucleocapsid
virion
well
doublestrand
dnacontain
cytoplasm
progeni
nucleocapsid
consequenti
interfer
cccdna
biosynthesi
de
novo
infect
intracellular
amplif
pathway
discoveri
human
sodium
taurochol
cotransport
polypeptid
hntcp
bona
fide
receptor
hbv
infect
hepatocyt
allow
establish
conveni
hbv
infect
cell
cultur
system
thu
establish
novel
ntcpexpress
human
cell
line
design
demonstr
suscept
hbv
infect
parent
cell
line
subclon
cell
exhibit
strong
contact
inhibit
growth
metabol
featur
similar
normal
hepatocyt
shown
fig
cccdna
becam
detect
earli
day
reach
maximum
level
day
post
infect
qpcr
convent
southern
blot
assay
hbv
pgrna
coreassoci
viral
dna
replic
intermedi
well
core
protein
also
accumul
sequenti
infect
cultur
hbsag
readili
detect
elisa
product
hbv
infect
cultur
media
order
investig
effect
cpam
hbv
infect
particularli
cccdna
synthesi
de
novo
infect
cell
mocktreat
treat
repres
hap
bay
sba
control
compound
entecavir
etv
myrcludex
b
myrb
start
h
hbv
infect
harvest
day
day
post
infect
expect
fig
myrb
acyl
peptid
deriv
hbv
larg
envelop
protein
block
viru
entri
inhibit
cccdna
format
consequenti
accumul
pgrna
core
dna
also
anticip
etv
hbv
dna
polymeras
inhibitor
affect
synthesi
cccdna
accumul
pgrna
inhibit
synthesi
core
dna
interestingli
bay
significantli
reduc
amount
cccdna
viral
pgrna
core
dna
also
proport
reduc
detail
time
cours
studi
span
first
four
day
post
infect
reveal
three
cpam
significantli
inhibit
cccdna
format
wherea
etv
fig
fig
lane
howev
etv
reduc
viral
rna
reduc
level
viral
pgrna
kb
mrna
presum
due
suppress
cccdna
transcript
character
inhibitori
effect
cpam
cccdna
biosynthesi
timeofaddit
dose
respons
experi
perform
agreement
mode
action
myrb
treatment
start
h
time
infect
effici
block
cccdna
format
wherea
delay
treatment
start
h
post
infect
complet
fail
inhibit
cccdna
format
fig
consist
kinet
cccdna
format
cell
cultur
system
fig
cpam
treatment
start
h
time
infect
reduc
cccdna
format
similar
effici
inhibitori
effect
significantli
reduc
treatment
start
h
post
infect
moreov
three
cpam
inhibit
cccdna
format
concentr
depend
manner
fig
result
agreement
report
publish
prepar
manuscript
bay
sba
deriv
inhibit
hbv
cccdna
synthesi
hbv
infect
human
primari
hepatocyt
investig
possibl
observ
inhibit
cpam
cccdna
format
due
inhibit
ntcpmediat
hbv
entri
examin
effect
hepat
viru
hdv
infect
cell
result
demonstr
myrb
effici
reduc
genom
antigenom
hdv
rna
log
etv
well
appar
alter
amount
hdv
rna
infect
cultur
fig
result
thu
impli
inhibit
cccdna
synthesi
cpam
due
interact
hbvspecif
compon
possibl
nucleocapsid
host
cellular
factor
entri
pathway
share
hbv
hdv
besid
synthes
incom
virion
dna
de
novo
infect
cccdna
infect
hepatocyt
also
amplifi
deliveri
rcdna
cytoplasm
progeni
nucleocapsid
nucleu
convers
cccdna
intracellular
cccdna
amplif
pathway
demonstr
function
cultur
cell
vivo
duck
hepat
b
viru
dhbv
infect
duck
regul
larg
envelop
protein
host
cellular
factor
cpam
inhibit
pgrna
encapsid
thu
preclud
viral
dna
replic
intracellular
amplif
cccdna
effect
intracellular
progeni
nucleocapsid
cccdna
amplif
investig
cell
directli
treat
compound
circumv
problem
depict
fig
first
arrest
hbv
dna
replic
cultur
cell
medium
without
tetracyclin
contain
revers
viral
dna
polymeras
inhibitor
foscarnet
trisodium
phosphonoform
pfa
short
four
day
arrest
hbv
dna
replic
predominantli
stage
incomplet
complet
minusstrand
dna
fig
cell
cultur
presenc
tetracyclin
stop
hbv
pgrna
transcript
integr
transgen
cellular
chromosom
also
absenc
pfa
allow
viral
dna
replic
cccdna
synthesi
resum
time
pfa
withdraw
mock
treatment
treatment
etv
initi
cell
harvest
indic
time
point
analys
hbv
core
dna
cccdna
synthesi
ident
cccdna
cell
cultur
system
confirm
resist
heat
denatur
convers
unitlength
dna
heat
denatur
ecori
digest
fig
shown
fig
upon
remov
pfa
cultur
medium
incomplet
complet
minu
strand
partial
doublestrand
complet
doubl
strand
hbv
dna
speci
includ
rcdna
sequenti
increas
h
fig
deprotein
rcdna
dprcdna
cccdna
becam
readili
detect
h
respect
fig
expect
etv
treatment
inhibit
elong
arrest
hbv
dna
speci
prevent
product
rcdna
well
dprcdna
cccdna
interestingli
although
treatment
inhibit
elong
minusstrand
partial
doublestrand
dna
cytoplasm
nucleocapsid
rcdna
accumul
cell
fig
howev
analysi
hirt
dna
indic
amount
dprcdna
appar
reduc
cpam
treatment
surpris
cccdna
readili
detect
earli
h
remov
pfa
cpamtreat
cell
experi
addit
cpam
extend
treatment
durat
support
notion
select
hap
sba
compound
reduc
accumul
cytoplasm
rcdnacontain
nucleocapsid
fig
significantli
acceler
cccdna
synthesi
intracellular
progeni
nucleocapsid
demonstr
two
differ
cccdna
assay
procedur
fig
fig
appar
contradict
effect
cpam
cytoplasm
rcdnacontain
nucleocapsid
accumul
kinet
cccdna
synthesi
cell
prompt
us
investig
whether
compound
inhibit
complet
rcdna
synthesi
andor
destabil
nucleocapsid
contain
matur
form
doublestrand
dna
latter
possibl
may
explain
observ
acceler
cccdna
format
intracellular
progeni
nucleocapsid
end
hbv
capsid
purifi
cytoplasm
fraction
pfatreat
cell
endogen
dna
polymeras
assay
perform
vitro
absenc
presenc
cpam
probe
integr
nucleocapsid
access
viral
dna
dnase
digest
test
complet
endogen
dna
polymeras
reaction
extract
viral
dna
southern
blot
analysi
viral
dna
speci
indic
rcdna
effici
synthes
vitro
endogen
dna
polymeras
reaction
dntp
provid
fig
furthermor
presenc
bay
inhibit
rcdna
synthesi
howev
rcdna
synthes
presenc
bay
suscept
dnase
digest
fig
henc
result
indic
cpam
inhibit
hbv
dna
synthesi
favor
hypothesi
select
cpam
specif
alter
structur
destabil
matur
rcdnacontain
nucleocapsid
facilit
rcdna
nuclear
deliveri
synthesi
cccdna
matur
rcdnacontain
nucleocapsid
constitut
small
fraction
total
cytoplasm
capsid
surpris
cpam
treatment
alter
amount
migrat
mobil
capsid
reveal
nativ
agaros
gel
electrophoresisbas
particl
gel
assay
fig
lower
panel
differenti
effect
cpam
cccdna
synthesi
de
novo
infect
intracellular
amplif
pathway
argu
compound
may
differ
effect
nucleocapsid
virion
cytoplasm
investig
possibl
purifi
hbv
virion
particl
blood
chronic
hbv
carrier
examin
effect
cpam
rcdna
synthesi
integr
nucleocapsid
vitro
endogen
dna
polymeras
reaction
describ
similar
result
obtain
cytoplasm
nucleocapsid
presenc
bay
inhibit
rcdna
synthesi
partial
doublestrand
virion
dna
confer
suscept
virion
rcdna
dnase
digest
manner
fig
investig
whether
cpam
directli
induc
structur
chang
partial
doublestrand
dnacontain
nucelocapsid
virion
particl
prepar
patient
serum
treat
cpam
endogen
dna
polymeras
reaction
without
dntp
follow
dnase
treatment
prior
dna
extract
result
show
three
test
cpam
render
virion
dna
speci
suscept
dnase
digest
concentrationdepend
manner
fig
henc
result
indic
irrespect
matur
stage
viral
dna
nucleocapsid
deriv
virion
particl
sensit
cpaminduc
structur
chang
expos
viral
dna
dnase
digest
encourag
observ
cpaminduc
virion
dna
suscept
dnase
depend
activ
dna
polymeras
reaction
ongo
dna
chain
elong
fig
examin
effect
cpam
capsid
purifi
cytoplasm
cell
endogen
dna
polymeras
reaction
buffer
without
dntp
shown
fig
rcdna
becam
suscept
dnase
digest
lower
concentr
less
matur
partial
doublestrand
dna
speci
becam
suscept
dnase
digest
gradual
increas
concentr
result
strongli
suggest
elong
posit
strand
dna
hepatocyt
may
increment
induc
structur
chang
nucleocapsid
confer
gradual
increas
sensit
cpam
induct
viral
dna
exposur
moreov
comprehens
doserespons
experi
reveal
minimum
concentr
bay
induc
complet
exposur
rcdna
approxim
respect
fig
compar
potenc
inhibit
nucleocapsid
assembl
viral
dna
replic
cell
kinet
studi
reveal
h
incub
requir
induc
signific
exposur
rcdna
h
exposur
suffici
bay
induc
extens
exposur
rcdna
fig
determin
kinet
cpam
induct
rcdna
exposur
cell
cell
cultur
tetfre
medium
day
treat
indic
period
time
cytoplasm
lysat
mocktreat
treat
dnase
extract
dna
shown
fig
treatment
h
induc
extens
rcdna
exposur
dnase
digest
although
result
present
indic
cpam
treatment
induc
exposur
rcdna
nucleocapsid
dnase
digest
extent
disrupt
structur
matur
nucleocapsid
differ
cpam
remain
determin
therefor
examin
whether
matur
viral
dna
speci
rcdna
doublestrand
linear
dsl
dna
still
associ
capsid
cpam
treatment
assumpt
cpam
treatment
sever
disrupt
matur
nuclocapsid
result
releas
viral
dna
anticip
rcdna
dsldna
speci
cosedi
form
capsid
howev
cpam
treatment
mildli
disrupt
matur
nucleocapsid
caus
exposur
viral
dna
still
associ
capsid
structur
anticip
see
rcdna
andor
dsldna
speci
cosedi
capsid
end
hbv
capsid
prepar
cell
mock
treat
incub
bay
endogen
dna
polymeras
reaction
without
dntp
reaction
fraction
sucros
densiti
gradient
ultracentrifug
amount
total
capsid
capsidassoci
dna
fraction
analyz
nativ
agaros
gel
electrophoresisbas
particl
gel
assay
shown
upper
panel
fig
compar
mocktreat
control
treatment
three
cpam
alter
sediment
profil
capsid
capsid
associ
hbv
dna
result
consist
observ
cpam
affect
matur
nuclocapsid
constitut
small
portion
total
capsid
fig
fig
howev
analysi
viral
dna
southern
blot
hybrid
fraction
reveal
rcdna
dsldna
lost
reduc
capsid
sediment
sucros
bay
treatment
major
rcdna
dsldna
still
cosedi
capsid
treatment
fig
lower
panel
due
small
amount
rcdna
dsldna
low
sensit
southern
blot
hybrid
assay
abl
identifi
locat
distribut
disassoci
dna
speci
gradient
nevertheless
result
indic
bay
treatment
like
induc
structur
chang
signific
enough
caus
loss
rcdna
dsldna
major
matur
nucleocapsid
less
activ
compound
might
induc
structur
chang
render
dna
content
suscept
dnase
digest
two
distinct
degre
conform
alter
may
correspond
subtl
increas
capsid
breath
versu
extens
rearrang
capsid
subunit
organ
genom
virus
wrap
capsid
protein
form
nucleocapsid
unlik
viral
enzym
often
host
cellular
homologu
host
cell
encod
protein
structur
function
similar
viral
capsid
protein
therefor
viral
capsid
protein
ideal
highli
select
antivir
target
addit
serv
vehicl
transmiss
viral
genom
host
cell
hbv
nucleocapsid
uniqu
function
viral
life
cycl
illustr
fig
first
hbv
dna
replic
occur
exclus
within
cytoplasm
nucleocapsid
revers
transcript
viral
pgrna
first
negativestrand
dna
doublestrand
rcdna
second
unlik
virus
progeni
nucleocapsid
one
destin
ie
secret
virion
hbv
progeni
nucleocapsid
also
deliv
rcdna
nuclei
synthes
cccdna
due
superinfect
exclus
reason
consid
activ
intracellular
amplif
pathway
key
determin
cccdna
pool
size
infect
hepatocyt
due
larg
amount
progeni
nucleocapsid
cytoplasm
intracellular
cccdna
amplif
pathway
must
actual
tightli
control
viral
host
factor
final
exclus
replic
nucleocapsid
spatiallycontrol
disassembl
deliveri
rcdna
nuclei
nuclear
pore
complex
protect
viral
dna
recognit
cytoplasm
dna
sensor
thu
favor
persist
infect
hbv
henc
specul
target
hbv
core
protein
may
disrupt
multipl
step
hbv
replic
activ
innat
immun
respons
viral
infect
cell
howev
mention
sever
distinct
chemotyp
hbv
cpam
shown
disrupt
viral
nucleocapsid
assembl
consequenti
inhibit
viral
genom
replic
effect
aspect
nucleocapsid
function
investig
herein
provid
evid
suggest
select
hap
sba
abl
interact
nucleocapsid
virion
matur
form
rcdnacontain
nucleocapsid
cytoplasm
subsequ
interfer
function
deliv
viral
rcdna
nuclei
cccdna
synthesi
although
structur
basi
cpam
target
highli
select
subpopul
nucleocapsid
remain
determin
result
consist
previou
find
matur
hbv
nucleocapsid
intrins
unstabl
fragil
probabl
due
stiff
rc
dsldna
impos
bend
energi
electrostat
repuls
capsid
shell
moreov
viral
dna
synthesi
nucleocapsid
assembl
mutant
dhbv
core
protein
serial
ntermin
inert
destabil
mutant
nucleocapsid
render
matur
viral
dna
select
sensit
nucleas
digest
therefor
possibl
intrins
instabl
matur
nucleocapsid
due
complet
doublestrand
dna
confer
select
sensit
cpam
induc
disassembl
consid
result
cpam
treatment
induc
access
form
virion
dna
either
rcdna
partial
doublestrand
dna
dnase
digest
possibl
explan
like
mani
virus
structur
shift
matur
nucleocapsid
may
occur
virion
assembl
secret
confer
suscept
cpam
moreov
recent
report
show
carboxyltermin
domain
core
protein
hypophosphoryl
dnacontain
virion
remain
hyperphosphoryl
intracellular
dnacontain
nucleocapsid
although
ctermin
argininerich
domain
hbv
core
protein
directli
involv
bind
cpam
dephosphoryl
may
alter
interact
core
protein
viral
dna
thu
affect
nucleocapsid
structur
manner
distinct
hyperphosphoryl
state
addit
sensit
partial
doublestrand
dnacontain
cytoplasm
nucleocapsid
increas
concentr
cpam
strongli
suggest
elong
positivestrand
dna
toward
rcdna
induc
increment
gradual
structur
chang
favor
specif
interact
cpam
structur
biolog
studi
purifi
doubl
strand
dnacontain
capsid
may
reveal
import
structur
differ
howev
technic
challeng
purifi
suffici
amount
rcdnacontain
hbv
capsid
cryoem
analys
although
studi
reveal
correl
alter
cccdna
synthesi
induct
nucleocapsid
destabl
cpam
molecular
mechan
cpaminduc
nucleocapsid
structur
chang
disrupt
cccdna
format
de
novo
infect
acceler
cccdna
synthesi
progeni
intracellular
nucleocapsid
remain
determin
howev
reason
specul
made
base
current
knowledg
illustr
fig
one
hand
de
novo
infect
cpam
may
interact
nucleocapsid
virion
endocyt
entri
immedi
releas
cytoplasm
induc
viral
dna
exposur
releas
nucleocapsid
prematur
disassembl
nucleocapsid
result
viral
dna
releas
decay
cytoplasm
dnase
arriv
nuclear
pore
complex
nuclear
import
subsequ
cccdna
synthesi
hand
due
shorter
distanc
travel
compar
de
novo
infect
intracellular
progeni
rcdnacontain
nucleocapsid
may
reach
nuclear
pore
complex
certain
stage
disassembl
cpaminduc
uncoat
actual
acceler
releas
rcdna
nuclei
thu
cccdna
format
cours
fraction
rcdna
decay
cytoplasm
may
also
occur
fact
interpret
agreement
recent
find
enhanc
destabil
matur
rcdna
contain
nucleocapsid
due
unidentifi
host
cellular
factor
mous
hepatocyt
singl
amino
acid
substitut
core
protein
significantli
reduc
accumul
rcdna
increas
dprcdna
cccdna
synthesi
escap
attent
releas
expos
rcdsldna
cytoplasm
may
activ
innat
dna
sensor
howev
cytokin
respons
detect
cpamtreat
cell
whether
due
defici
cyclic
gmpamp
synthas
cga
stimul
interferon
gene
sting
pathway
hepatocyt
hepatoma
cell
effici
digest
releas
viral
dna
cytoplasm
nucleas
current
investig
inhibit
cccdna
synthesi
de
novo
infect
obvious
benefici
therapeut
effect
acceler
intracellular
cccdna
amplif
detriment
howev
potent
inhibit
pgrna
encapsid
cpam
quickli
block
viral
dna
replic
product
matur
progeni
nucleocapsid
consequenti
cccdna
synthesi
therefor
chanc
cpam
acceler
cccdna
synthesi
antivir
therapi
initi
period
treatment
promot
cccdna
synthesi
preexist
matur
nucleocapsid
hbv
infect
cell
fortun
treatment
cell
support
steadyst
hbv
dna
replic
etv
cpam
mimic
initi
stage
antivir
treatment
vivo
observ
signific
increas
cccdna
accumul
within
first
h
treatment
instead
similar
etv
cpam
prevent
amplif
cccdna
pool
prolong
treatment
compar
mocktreat
control
fig
fact
result
consist
observ
cpam
treatment
primari
human
hepatocyt
establish
hbv
infect
alter
amount
cccdna
take
togeth
result
impli
cpam
significantli
increas
amount
cccdna
acceler
ongo
cccdna
synthesi
condit
fast
cccdna
synthesi
releas
pfa
arrest
hbv
dna
replic
acceler
low
neglig
rate
cccdna
synthesi
significantli
increas
amount
cccdna
cell
establish
hbv
infect
mechanist
state
possibl
cpaminduc
disassembl
matur
nucleocapsid
occur
near
nuclear
pore
complex
may
facilit
import
rcdna
nuclu
cccdna
synthesi
matur
nucleocapsid
statu
may
exist
signific
amount
hepatocyt
establish
infect
nevertheless
care
monitor
cccdna
synthesi
earli
phase
cpam
treatment
vivo
anim
clinic
trial
pretreat
combin
viral
dna
polymeras
inhibitor
might
consid
cell
line
obtain
dr
christoph
seeger
fox
chase
cancer
center
philadelphia
support
hbv
pgrna
transcript
subsequ
viral
dna
replic
tetracyclin
tet
induc
manner
maintain
previous
describ
cell
line
deriv
atcc
atcc
maintain
medium
supplement
fb
gemini
bioproduct
uml
penicillin
streptomycin
entecavir
etv
gift
dr
william
mason
fox
chase
cancer
center
philadelphia
foscarnet
purchas
sigma
capsid
assembl
modul
describ
previous
myrcludex
b
gift
dr
stephan
urban
heidelberg
univers
germani
alphainterferon
purchas
pbl
assay
scienc
rabbit
antihbc
antibodi
obtain
dako
human
sodium
taurochol
cotransport
polypeptid
ntcp
gene
code
sequenc
amplifi
cdna
clone
purchas
origen
carboxyltermin
tag
ad
pcr
amplif
primer
harbor
tag
sequenc
noti
bam
hi
restrict
enzym
site
purifi
pcr
fragment
digest
restrict
enzym
bam
hi
subsequ
clone
pqcxip
vector
clontech
vsv
g
protein
pseudotyp
retrovirus
packag
cell
previous
describ
cell
line
stabli
express
human
ntcp
establish
infect
cell
line
pseudotyp
retrovirus
select
medium
contain
puromycin
puromycinresist
cell
expand
cell
line
design
proper
express
ntcp
confirm
immunofluoresc
western
blot
assay
cell
seed
collagenco
plate
densiti
cell
per
well
cultur
complet
dmem
medium
contain
dimethyl
sulfoxid
dmso
one
day
later
cell
infect
hbv
prepar
cell
cultur
media
moi
genom
equival
per
cell
dmem
contain
inoculum
remov
h
post
infect
cultur
maintain
complet
dmem
medium
contain
dmso
harvest
cell
cultur
deriv
hdv
particl
gener
describ
previous
briefli
cell
obtain
dr
christoph
seeger
fox
chase
cancer
center
philadelphia
cotransfect
plasmid
contain
three
copi
hdv
cdna
sequenc
plasmid
express
hbv
envelop
protein
l
hdv
particl
harvest
media
day
post
transfect
clarif
centrifug
particl
precipit
presenc
pellet
dissolv
tan
buffer
mm
trishcl
ph
mm
nacl
volum
origin
cultur
medium
infect
cell
seed
collagenco
plate
densiti
cell
per
well
cultur
complet
dmem
medium
contain
dimethyl
sulfoxid
dmso
one
day
later
cell
infect
hdv
moi
genom
equival
per
cell
dmem
contain
inoculum
remov
h
post
infect
cultur
maintain
complet
dmem
medium
contain
dmso
harvest
intracellular
hdv
genom
antigenom
rna
quantifi
qrtpcr
use
strandspecif
primer
describ
previous
hbv
virion
prepar
hbv
carrier
serum
bioreclam
ivt
complet
resourc
biolog
sucros
gradient
centrifug
briefli
ml
human
sera
layer
onto
wtvol
sucros
cushion
nacl
trishcl
ph
centrifug
h
rpm
rotor
supernat
fluid
remov
pellet
dissolv
tne
buffer
nacl
trishcl
ph
mm
edta
prepar
intracellular
hbv
capsid
cell
cultur
tetracyclinefre
medium
without
mm
foscarnet
pfa
day
daili
medium
chang
cell
lyse
chill
lysi
buffer
contain
mm
trishcl
ph
mm
edta
nonidet
sucros
ice
minut
lysat
centrifug
g
min
remov
nuclei
cell
debri
clarifi
supernat
overlaid
onto
ww
sucros
gradient
centrifug
rpm
h
use
beckman
rotor
nineteen
fraction
collect
bottom
cushion
ten
microlit
fraction
dotblot
onto
nitrocellulos
membran
hbv
core
protein
detect
incub
rabbit
antibodi
hbv
core
protein
dako
bound
antibodi
detect
irdy
secondari
antibodi
visual
licor
odyssey
system
hbv
core
proteinposit
fraction
pool
togeth
sucros
concentr
adjust
addit
tne
buffer
dilut
sampl
overlaid
sucros
cushion
centrifug
rpm
h
use
beckman
rotor
pellet
resuspend
tne
buffer
endogen
dna
polymeras
reaction
epr
mixtur
assembl
hbv
virion
capsid
prepar
epr
buffer
consist
nacl
trishcl
ph
mm
mm
dithiothreitol
volvol
nonidet
dntp
capsid
assembl
modul
ad
indic
mm
specifi
final
concentr
respect
water
ad
bring
reaction
volum
incub
indic
period
time
reaction
subject
extract
viral
dna
without
prior
dnase
digest
min
viral
dna
resolv
agaros
gel
transfer
onto
hybondxl
membran
membran
probe
label
minu
strand
specif
fulllength
hbv
riboprob
cytoplasm
hbv
capsid
analyz
nativ
agaros
gel
electrophoresisbas
assay
briefli
ten
microlit
endogen
dna
polymeras
reaction
fraction
sucros
gradient
centrifug
resolv
electrophoresi
agaros
gel
transfer
nitrocellulos
membran
blot
tne
buffer
mm
trishcl
ph
mm
nacl
mm
edta
hbv
capsid
membran
detect
procedur
describ
previous
two
hundr
microlit
purifi
hbv
capsid
mix
reaction
buffer
contain
nacl
trishcl
ph
mm
mm
dithiothreitol
volvol
nonidet
capsid
assembl
modul
ad
indic
water
provid
bring
reaction
volum
incub
indic
period
time
reaction
load
onto
linear
sucros
gradient
tne
buffer
spun
rpm
hr
beckman
rotor
fraction
collect
bottom
centrifug
tube
blood
collect
set
sucros
concentr
fraction
measur
refractor
mettler
toledo
rest
fraction
mix
tne
buffer
pellet
centrifug
rpm
hr
pellet
dissolv
tne
buffer
capsid
solut
fraction
agaros
gel
electrophoresi
transfer
nitrocellulos
membran
detect
hbv
capsid
probe
antihbcag
antibodi
viral
dna
extract
remain
sampl
reaction
detect
southern
blot
hybrid
minu
strandspecif
fulllength
hbv
riboprob
